NASDAQ:BLTE Belite Bio (BLTE) Stock Price, News & Analysis $61.85 -0.46 (-0.74%) Closing price 04:00 PM EasternExtended Trading$61.91 +0.06 (+0.10%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Belite Bio Stock (NASDAQ:BLTE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Belite Bio alerts:Sign Up Key Stats Today's Range$61.01▼$62.4850-Day Range$56.81▼$67.2952-Week Range$43.70▼$86.53Volume22,622 shsAverage Volume73,428 shsMarket Capitalization$1.97 billionP/E RatioN/ADividend YieldN/APrice Target$96.67Consensus RatingBuy Company Overview Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd. Read More Belite Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreBLTE MarketRank™: Belite Bio scored higher than 36% of companies evaluated by MarketBeat, and ranked 705th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBelite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBelite Bio has only been the subject of 2 research reports in the past 90 days.Read more about Belite Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Belite Bio are expected to grow in the coming year, from ($1.17) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Belite Bio is -45.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Belite Bio is -45.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBelite Bio has a P/B Ratio of 13.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Belite Bio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.60% of the float of Belite Bio has been sold short.Short Interest Ratio / Days to CoverBelite Bio has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Belite Bio has recently increased by 5.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBelite Bio does not currently pay a dividend.Dividend GrowthBelite Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.60% of the float of Belite Bio has been sold short.Short Interest Ratio / Days to CoverBelite Bio has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Belite Bio has recently increased by 5.44%, indicating that investor sentiment is decreasing significantly. News and Social Media0.8 / 5News Sentiment-0.50 News SentimentBelite Bio has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Belite Bio this week, compared to 3 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Belite Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.53% of the stock of Belite Bio is held by institutions.Read more about Belite Bio's insider trading history. Receive BLTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BLTE Stock News HeadlinesBelite Bio Inc ADR News (BLTE) - Investing.comJuly 23 at 3:56 AM | investing.comBelite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic AtrophyJuly 2, 2025 | globenewswire.comI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.July 24 at 2:00 AM | Timothy Sykes (Ad)Belite Bio stock holds $80 target on FDA breakthrough nodMay 23, 2025 | investing.comBelite Bio, Inc: Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt DiseaseMay 21, 2025 | finanznachrichten.deBelite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt DiseaseMay 21, 2025 | globenewswire.comBelite Bio stock retains Overweight rating at Cantor FitzgeraldMay 17, 2025 | uk.investing.comWe're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash BurnMay 16, 2025 | finance.yahoo.comSee More Headlines BLTE Stock Analysis - Frequently Asked Questions How have BLTE shares performed this year? Belite Bio's stock was trading at $63.10 at the beginning of 2025. Since then, BLTE shares have decreased by 2.0% and is now trading at $61.85. How were Belite Bio's earnings last quarter? Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) posted its earnings results on Monday, March, 17th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.02. Read the conference call transcript. When did Belite Bio IPO? Belite Bio (BLTE) raised $36 million in an initial public offering on Friday, April 29th 2022. The company issued 6,000,000 shares at a price of $5.50-$6.50 per share. Who are Belite Bio's major shareholders? Top institutional shareholders of Belite Bio include GAMMA Investing LLC. How do I buy shares of Belite Bio? Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Belite Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Belite Bio investors own include Paycom Software (PAYC), Centrus Energy (LEU), Planet Labs PBC (PL), uniQure (QURE), Grayscale Ethereum Trust (ETH) (ETHE), Marathon Oil (MRO) and Vale (VALE). Company Calendar Last Earnings3/17/2025Today7/24/2025Next Earnings (Estimated)8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BLTE CIK1889109 Webbelitebio.com Phone858-246-6240FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for Belite Bio$96.67 High Price Target$110.00 Low Price Target$80.00 Potential Upside/Downside+56.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.14 million Net MarginsN/A Pretax MarginN/A Return on Equity-32.07% Return on Assets-30.91% Debt Debt-to-Equity RatioN/A Current Ratio24.31 Quick Ratio24.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.72 per share Price / Book13.10Miscellaneous Outstanding Shares31,840,000Free Float27,607,000Market Cap$1.97 billion OptionableNot Optionable Beta-1.50 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:BLTE) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.